Annual Total Liabilities
$136.32 M
+$59.14 M+76.64%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual total liabilities is $136.32 million, with the most recent change of +$59.14 million (+76.64%) on December 31, 2023.
- During the last 3 years, LXRX annual total liabilities has risen by +$88.90 million (+187.49%).
- LXRX annual total liabilities is now -62.98% below its all-time high of $368.27 million, reached on December 31, 2017.
Performance
LXRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$142.61 M
+$9.23 M+6.92%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly total liabilities is $142.61 million, with the most recent change of +$9.23 million (+6.92%) on September 30, 2024.
- Over the past year, LXRX quarterly total liabilities has increased by +$14.26 million (+11.11%).
- LXRX quarterly total liabilities is now -61.28% below its all-time high of $368.27 million, reached on December 31, 2017.
Performance
LXRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
LXRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +76.6% | +11.1% |
| 3 y3 years | +187.5% | +199.2% |
| 5 y5 years | -56.1% | -49.0% |
LXRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +484.7% | at high | +511.7% |
| 5 y | 5-year | -54.6% | +484.7% | -57.2% | +511.7% |
| alltime | all time | -63.0% | +943.4% | -61.3% | +1499.0% |
Lexicon Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $142.61 M(+6.9%) |
| Jun 2024 | - | $133.38 M(+3.9%) |
| Mar 2024 | - | $128.35 M(-5.8%) |
| Dec 2023 | $136.32 M(+76.6%) | $136.32 M(-0.5%) |
| Sep 2023 | - | $136.97 M(+5.1%) |
| Jun 2023 | - | $130.36 M(+74.6%) |
| Mar 2023 | - | $74.67 M(-3.2%) |
| Dec 2022 | $77.17 M(+231.0%) | $77.17 M(+61.9%) |
| Sep 2022 | - | $47.67 M(+14.9%) |
| Jun 2022 | - | $41.49 M(-4.6%) |
| Mar 2022 | - | $43.48 M(+86.5%) |
| Dec 2021 | $23.31 M(-50.8%) | $23.31 M(-34.7%) |
| Sep 2021 | - | $35.73 M(+3.7%) |
| Jun 2021 | - | $34.44 M(-15.4%) |
| Mar 2021 | - | $40.71 M(-14.1%) |
| Dec 2020 | $47.42 M(-84.2%) | $47.42 M(-48.1%) |
| Sep 2020 | - | $91.29 M(-72.6%) |
| Jun 2020 | - | $333.23 M(+5.5%) |
| Mar 2020 | - | $315.79 M(+5.0%) |
| Dec 2019 | $300.61 M(-3.2%) | $300.61 M(+7.4%) |
| Sep 2019 | - | $279.88 M(-6.1%) |
| Jun 2019 | - | $298.03 M(-2.0%) |
| Mar 2019 | - | $304.20 M(-2.0%) |
| Dec 2018 | $310.54 M(-15.7%) | $310.54 M(-8.6%) |
| Sep 2018 | - | $339.59 M(+0.5%) |
| Jun 2018 | - | $338.01 M(-6.3%) |
| Mar 2018 | - | $360.62 M(-2.1%) |
| Dec 2017 | $368.27 M(+15.7%) | $368.27 M(+46.7%) |
| Sep 2017 | - | $251.11 M(-2.4%) |
| Jun 2017 | - | $257.20 M(-1.7%) |
| Mar 2017 | - | $261.66 M(-17.8%) |
| Dec 2016 | $318.22 M(-13.1%) | $318.22 M(-4.1%) |
| Sep 2016 | - | $331.76 M(-2.7%) |
| Jun 2016 | - | $340.80 M(-4.9%) |
| Mar 2016 | - | $358.46 M(-2.1%) |
| Dec 2015 | $366.11 M(+95.4%) | $366.11 M(+89.5%) |
| Sep 2015 | - | $193.20 M(+4.7%) |
| Jun 2015 | - | $184.49 M(-1.4%) |
| Mar 2015 | - | $187.07 M(-0.2%) |
| Dec 2014 | $187.36 M(+80.2%) | $187.36 M(+70.8%) |
| Sep 2014 | - | $109.70 M(+2.1%) |
| Jun 2014 | - | $107.40 M(+4.4%) |
| Mar 2014 | - | $102.83 M(-1.1%) |
| Dec 2013 | $104.00 M(-1.0%) | $104.00 M(-8.6%) |
| Sep 2013 | - | $113.75 M(+5.0%) |
| Jun 2013 | - | $108.31 M(+3.1%) |
| Mar 2013 | - | $105.07 M(-0.0%) |
| Dec 2012 | $105.10 M | $105.10 M(+0.0%) |
| Sep 2012 | - | $105.08 M(-22.8%) |
| Jun 2012 | - | $136.16 M(+1.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $133.82 M(+0.7%) |
| Dec 2011 | $132.94 M(+10.9%) | $132.94 M(+6.2%) |
| Sep 2011 | - | $125.22 M(+2.9%) |
| Jun 2011 | - | $121.73 M(-1.9%) |
| Mar 2011 | - | $124.09 M(+3.5%) |
| Dec 2010 | $119.86 M(+27.2%) | $119.86 M(+17.5%) |
| Sep 2010 | - | $102.02 M(+45.5%) |
| Jun 2010 | - | $70.12 M(-22.4%) |
| Mar 2010 | - | $90.31 M(-4.2%) |
| Dec 2009 | $94.26 M(+43.5%) | $94.26 M(+0.5%) |
| Sep 2009 | - | $93.78 M(+0.6%) |
| Jun 2009 | - | $93.22 M(+31.0%) |
| Mar 2009 | - | $71.16 M(+8.3%) |
| Dec 2008 | $65.68 M(-20.6%) | $65.68 M(-5.8%) |
| Sep 2008 | - | $69.76 M(-4.0%) |
| Jun 2008 | - | $72.65 M(-1.1%) |
| Mar 2008 | - | $73.42 M(-11.2%) |
| Dec 2007 | $82.72 M(-21.0%) | $82.72 M(-4.7%) |
| Sep 2007 | - | $86.82 M(-4.7%) |
| Jun 2007 | - | $91.12 M(-7.4%) |
| Mar 2007 | - | $98.36 M(-6.1%) |
| Dec 2006 | $104.77 M(-21.2%) | $104.77 M(-5.4%) |
| Sep 2006 | - | $110.70 M(-8.4%) |
| Jun 2006 | - | $120.82 M(-4.4%) |
| Mar 2006 | - | $126.37 M(-4.9%) |
| Dec 2005 | $132.91 M(+47.0%) | $132.91 M(+2.9%) |
| Sep 2005 | - | $129.11 M(+31.4%) |
| Jun 2005 | - | $98.25 M(+22.0%) |
| Mar 2005 | - | $80.51 M(-10.9%) |
| Dec 2004 | $90.39 M(-23.4%) | $90.39 M(-3.0%) |
| Sep 2004 | - | $93.14 M(+9.7%) |
| Jun 2004 | - | $84.88 M(-22.9%) |
| Mar 2004 | - | $110.15 M(-6.6%) |
| Dec 2003 | $117.98 M(+270.2%) | $117.98 M(+281.8%) |
| Sep 2003 | - | $30.90 M(-6.6%) |
| Jun 2003 | - | $33.07 M(+24.1%) |
| Mar 2003 | - | $26.65 M(-16.4%) |
| Dec 2002 | $31.87 M(+47.4%) | $31.87 M(+78.2%) |
| Sep 2002 | - | $17.89 M(-4.4%) |
| Jun 2002 | - | $18.71 M(-5.3%) |
| Mar 2002 | - | $19.75 M(-8.6%) |
| Dec 2001 | $21.62 M(+65.5%) | $21.62 M(-4.9%) |
| Sep 2001 | - | $22.72 M(-14.1%) |
| Jun 2001 | - | $26.45 M(+114.1%) |
| Mar 2001 | - | $12.35 M(-5.5%) |
| Dec 2000 | $13.06 M(-7.9%) | $13.06 M(+46.5%) |
| Sep 2000 | - | $8.92 M(-25.5%) |
| Jun 2000 | - | $11.97 M(-15.0%) |
| Mar 2000 | - | $14.09 M |
| Dec 1999 | $14.18 M | - |
FAQ
- What is Lexicon Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual total liabilities year-on-year change?
- What is Lexicon Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly total liabilities year-on-year change?
What is Lexicon Pharmaceuticals annual total liabilities?
The current annual total liabilities of LXRX is $136.32 M
What is the all time high annual total liabilities for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual total liabilities is $368.27 M
What is Lexicon Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, LXRX annual total liabilities has changed by +$59.14 M (+76.64%)
What is Lexicon Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of LXRX is $142.61 M
What is the all time high quarterly total liabilities for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly total liabilities is $368.27 M
What is Lexicon Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, LXRX quarterly total liabilities has changed by +$14.26 M (+11.11%)